Diffuse Lung Disease |

Decreased Plasmatic Levels of Histidine-Rich Glycoprotein in Patients With Idiopathic Pulmonary Fibrosis: Relationship With Lung Diffusion Capacity and Walking Test FREE TO VIEW

Glenda Ernst, PhD; Ezequiel Dantas; Fabian Caro; Santiago Rossi; Antonella Merlotti; Augusto Varesse; Gabriel Duette; Jorge Geffner; Pedro Grynblat
Author and Funding Information

Hospital Maria Ferrer, Buenos Aires, Argentina

Chest. 2014;146(4_MeetingAbstracts):372A. doi:10.1378/chest.1984404
Text Size: A A A
Published online


SESSION TITLE: Interstitial Lung Disease Posters II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a chronic and fibrosing disease characterized by a progressive loss of lung function and poor prognosis. The pathogenesis of the IPF is complex and the mechanisms involved are still unknown. Histidine-rich glicoprotein (HRG) is a plasma protein that interacts with many ligands and regulates a number of important biological processes. HRG is constitutively present at high concentrations in plasma. Previous studies have shown that HRG is able to modulate the activation of the fibroblast growth factor receptor. The aim of this study was to determine whether the levels of HRG in plasma of IPF patients were predictive of lung function.

METHODS: We collected plasma samples from 14 IPF patients (12/2: males/female); with an average age of 62.5 ± 2.0 years; 9 ex-smokers, 1 current-smoker and 4 non-smokers. Eleven of them showed typical topographic images (HRTC) of IPF, and the others presented a suggestive pattern. We confirmed diagnosis by lung biopsy in 3 patients. As the control group we used plasma from 10 healthy non-smoking subjects. Plasma levels of HRG were measured by ELISA. Data were analyzed with Mann-Whitney test and linear regression analyses.

RESULTS: We observed a significant decrease of HRG plasma levels in IPF patients compared with the control group (81.9 ± 5.3 μg/ml vs 103.8 ± 4.1 μg/ml; p<0.001). We found a positive and significant relationship between HRG plasma levels and both DLCO (percentage of predicted value) and 6 minutes walking test (meters walked) (Spearman r = 0.39; p<0.05, and r = 0.61; p<0.001, respectively). We also found a positive relationship between the decreased levels of HRG in plasma and pack/years smoked (r = 0.66; p<0.001).

CONCLUSIONS: Our results illustrate that a decreased plasmatic levels of HRG is associated to the progression of illness in IPF patients.

CLINICAL IMPLICATIONS: Our data suggest that HRG could be used as a biomarker to evaluate the evolution and prognosis of IPF patients, supporting the need for a larger study.

DISCLOSURE: The following authors have nothing to disclose: Glenda Ernst, Ezequiel Dantas, Fabian Caro, Santiago Rossi, Antonella Merlotti, Augusto Varesse, Gabriel Duette, Jorge Geffner, Pedro Grynblat

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543